3 completed, 2 not yet recruiting, 2 terminated, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 2 Phase 3, 1 Phase 4.
Follow HER2 Positive: new trials by email Literature Review of HER2 Positive trials Research Report on HER2 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-09-18 | 2026-10-16 |
| Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer Trastuzumab +Cetuximab β+Irinotecan - HER2 Positive, Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 34 | 2025-07-11 | 2025-07-10 |
| Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor - Metastatic Biliary Tract Cancer, HER2 Positive | Phase 4 | Not yet recruiting | Eastern Hepatobiliary Surgery Hospital | 35 | 2025-02-01 | 2025-02-10 |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer Pyrotinib Maleate Tablets, Albumin Paclitaxel, Trastuzumab - Breast Cancer, HER2 Positive | Phase 1 / Phase 2 | Unknown | West China Hospital | 20 | 2019-11-01 | 2019-11-05 |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Lucitanib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 178 | 2014-09-09 | 2020-06-23 |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 PTC+Pertuzumab, FEC-T+Pertuzumab - Breast Cancer, HER2 Positive | Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 437 | 2013-12-01 | 2024-03-29 |
| Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules AZD5363 - Advanced Solid Malignancy, Safety and Tolerability | Phase 1 | Completed | AstraZeneca | 285 | 2010-12-01 | 2025-06-29 |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer Lapatinib and Capecitabine and Vinorelbine - Metastatic Breast Cancer, HER2 Positive | Phase 1 | Terminated | Sponsor GmbH | 12 | 2010-10-01 | 2014-11-21 |
| Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study paclitaxel, trastuzumab and carboplatin - Breast Cancer, HER2 Positive | Phase 2 | Completed | The Netherlands Cancer Institute | 111 | 2008-09-01 | 2012-05-11 |
| Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer lapatinib and temozolomide - Metastatic Breast Cancer, Brain Metastases | Phase 1 | Completed | Jules Bordet Institute | 18 | 2008-01-01 | 2012-09-19 |
Breast Neoplasms (8) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Ovarian Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (10) · Breast Diseases (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Nervous System Diseases (2) · Adnexal Diseases (1) · Biliary Tract Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Colonic Diseases (1) · Congenital Abnormalities (1)
Trastuzumab (4) · Carboplatin (2) · Lapatinib (2) · Paclitaxel (2) · pertuzumab (2) · Capecitabine (1) · Cyclophosphamide (1) · E-3810 (1) · Epirubicin (1) · Fluorouracil (1) · Gemcitabine (1) · Irinotecan (1) · Temozolomide (1) · Vinorelbine (1) · capivasertib (1)
The Netherlands Cancer Institute (2) · AstraZeneca (1) · Clovis Oncology, Inc. (1) · Daiichi Sankyo (1) · Eastern Hepatobiliary Surgery Hospital (1) · Jules Bordet Institute (1) · Sponsor GmbH (1) · Sun Yat-sen University (1) · West China Hospital (1)
Netherlands (3) · United States (3) · China (2) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Evandro de Azambuja, MD, PhD (1) · G S Sonke, MD (1) · Gabe S Sonke, MD (1) · Gaia Schiavon, MSD (1) · Ting Luo, MD (1) · Udai Banerji, MD, PhD (1) · Ulrike Soeling, MD (1)
PMID 29066505, PMID 30413379, PMID 32312891, PMID 33863913, PMID 34014249, PMID 34250397, PMID 35242683, PMID 35844029
2008 (1)